MARKET

ALPMY

ALPMY

Astellas Pharma
OTCPK
14.10
-0.18
-1.26%
Closed 12:33 01/16 EST
OPEN
14.06
PREV CLOSE
14.28
HIGH
14.13
LOW
14.06
VOLUME
3.24K
TURNOVER
45.74K
52 WEEK HIGH
14.50
52 WEEK LOW
8.18
MARKET CAP
25.26B
P/E (TTM)
30.06
1D
5D
1M
3M
1Y
5Y
1D
Citi Sticks to Its Hold Rating for Astellas Pharma (ALPMF)
TipRanks · 6h ago
Weekly Report: what happened at ALPMY last week (0112-0116)?
Weekly Report · 15h ago
Weekly Report: what happened at ALPMY last week (0105-0109)?
Weekly Report · 01/12 09:27
Weekly Report: what happened at ALPMY last week (1229-0102)?
Weekly Report · 01/05 09:26
Weekly Report: what happened at ALPMY last week (1222-1226)?
Weekly Report · 12/29/2025 09:25
Weekly Report: what happened at ALPMY last week (1215-1219)?
Weekly Report · 12/22/2025 09:25
Astellas Reports Positive Phase 3 EV-304 Results For PADCEV Combo In Muscle-Invasive Bladder Cancer
NASDAQ · 12/18/2025 06:14
Merck's Keytruda-Padcev Combo Boosts Survival In Pivotal Bladder Cancer Trial
Benzinga · 12/17/2025 17:45
More
About ALPMY
Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.

Webull offers Astellas Pharma Inc stock information, including OTCPK: ALPMY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALPMY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALPMY stock methods without spending real money on the virtual paper trading platform.